Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The Emerging Landscape of Immune Cell Therapies
Evan W. Weber, Marcela V. Maus, Crystal L. Mackall
Cell (2020) Vol. 181, Iss. 1, pp. 46-62
Open Access | Times Cited: 361

Showing 1-25 of 361 citing articles:

Intratumoral heterogeneity in cancer progression and response to immunotherapy
Ilio Vitale, Efrat Shema, Sherene Loi, et al.
Nature Medicine (2021) Vol. 27, Iss. 2, pp. 212-224
Closed Access | Times Cited: 567
Transient rest restores functionality in exhausted CAR-T cells through epigenetic remodeling
Evan W. Weber, Kevin R. Parker, Elena Sotillo, et al.
Science (2021) Vol. 372, Iss. 6537
Open Access | Times Cited: 447
Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response
Dongrui Wang, Xianlin Wu, Yingli Sun
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 287
Beyond conventional immune-checkpoint inhibition — novel immunotherapies for renal cell carcinoma
David A. Braun, Ziad Bakouny, Laure Hirsch, et al.
Nature Reviews Clinical Oncology (2021) Vol. 18, Iss. 4, pp. 199-214
Open Access | Times Cited: 256
Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
Ying Gong, Roel G. J. Klein Wolterink, Jianxiang Wang, et al.
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 248
Synthetic biology 2020–2030: six commercially-available products that are changing our world
Christopher A. Voigt
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 221
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Max Jan, Irene Scarfò, Rebecca C. Larson, et al.
Science Translational Medicine (2021) Vol. 13, Iss. 575
Open Access | Times Cited: 197
Engineering strategies to enhance oncolytic viruses in cancer immunotherapy
Yaomei Tian, Daoyuan Xie, Yang Li
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 160
CD8+ T cells in the cancer-immunity cycle
Josephine R. Giles, Anna-Maria Globig, Susan M. Kaech, et al.
Immunity (2023) Vol. 56, Iss. 10, pp. 2231-2253
Open Access | Times Cited: 158
Ultrasound-controllable engineered bacteria for cancer immunotherapy
Mohamad H. Abedi, Michael S. Yao, David R. Mittelstein, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 157
Frequent aneuploidy in primary human T cells after CRISPR–Cas9 cleavage
Alessio D. Nahmad, Eli Reuveni, Ella Goldschmidt, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 12, pp. 1807-1813
Open Access | Times Cited: 152
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Paul Shafer, Lauren Kelly, Valentina Hoyos
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 149
Targeted delivery of CRISPR-Cas9 and transgenes enables complex immune cell engineering
Jennifer Hamilton, Connor A. Tsuchida, David N. Nguyen, et al.
Cell Reports (2021) Vol. 35, Iss. 9, pp. 109207-109207
Open Access | Times Cited: 148
Thermal immuno-nanomedicine in cancer
Zhe Yang, Di Gao, Jing Zhao, et al.
Nature Reviews Clinical Oncology (2023) Vol. 20, Iss. 2, pp. 116-134
Closed Access | Times Cited: 142
Targeting public neoantigens for cancer immunotherapy
Alexander H. Pearlman, Michael S. Hwang, Maximilian F. Konig, et al.
Nature Cancer (2021) Vol. 2, Iss. 5, pp. 487-497
Open Access | Times Cited: 130
Combination cancer immunotherapies: Emerging treatment strategies adapted to the tumor microenvironment
Nicole Kirchhammer, Marcel P. Trefny, Priska Auf der Maur, et al.
Science Translational Medicine (2022) Vol. 14, Iss. 670
Closed Access | Times Cited: 117
The future of engineered immune cell therapies
Darrell J. Irvine, Marcela V. Maus, David Mooney, et al.
Science (2022) Vol. 378, Iss. 6622, pp. 853-858
Open Access | Times Cited: 116
Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control
Ian C. Miller, Ali Zamat, Lee-Kai Sun, et al.
Nature Biomedical Engineering (2021) Vol. 5, Iss. 11, pp. 1348-1359
Open Access | Times Cited: 114
Cell‐Based Delivery Systems: Emerging Carriers for Immunotherapy
Zhaoting Li, Yixin Wang, Yingyue Ding, et al.
Advanced Functional Materials (2021) Vol. 31, Iss. 23
Closed Access | Times Cited: 104
Immunology and immunotherapy of cholangiocarcinoma
Tim F. Greten, Robert F. Schwabe, Nabeel Bardeesy, et al.
Nature Reviews Gastroenterology & Hepatology (2023) Vol. 20, Iss. 6, pp. 349-365
Closed Access | Times Cited: 89
Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes
Dana V. Foss, Joseph J. Muldoon, David N. Nguyen, et al.
Nature Biomedical Engineering (2023) Vol. 7, Iss. 5, pp. 647-660
Open Access | Times Cited: 72
The opportunities and challenges in immunotherapy: Insights from the regulation of PD-L1 in cancer cells
Qingyu Lin, Xingwen Wang, Ying Hu
Cancer Letters (2023) Vol. 569, pp. 216318-216318
Open Access | Times Cited: 53
FOXO1 is a master regulator of memory programming in CAR T cells
Alexander Doan, Katherine P. Mueller, Andy Y. Chen, et al.
Nature (2024) Vol. 629, Iss. 8010, pp. 211-218
Open Access | Times Cited: 53
Engineering RNA export for measurement and manipulation of living cells
Felix Horns, Joe A. Martinez, Chengcheng Fan, et al.
Cell (2023) Vol. 186, Iss. 17, pp. 3642-3658.e32
Open Access | Times Cited: 45
Inosine induces stemness features in CAR-T cells and enhances potency
Dorota D. Klysz, Carley Fowler, Meena Malipatlolla, et al.
Cancer Cell (2024) Vol. 42, Iss. 2, pp. 266-282.e8
Open Access | Times Cited: 44
Page 1 - Next Page

Scroll to top